Amino.Desk

PE-22-28

Updated Nov 17, 2026 · Clinical review: pending

PE-22-28 is a seven-amino-acid peptide sold as a mood and focus compound. It was designed by French researchers as an improved version of a natural peptide called spadin. All of the evidence is in rodents.

What it is

A shortened analog of spadin. It blocks a potassium channel in nerve cells called TREK-1, which makes those cells more responsive. In laboratory tests it blocked the channel far more strongly than spadin and lasted longer in the body.

What the evidence shows

The 2017 paper that introduced it reported antidepressant-like behavior in mice and signs of new nerve cell growth. The authors called it a promising alternative to spadin for treating depression.

No human trial of PE-22-28 or of spadin has been completed or registered, according to a clinical summary last updated in September 2026.

Legal status

Reported dosing

We do not publish a protocol for this compound.

No dose has been established in people.

Safety

Common questions

Has PE-22-28 been tested in humans?

No. The evidence is from rodents.

What does PE-22-28 do?

It blocks the TREK-1 potassium channel, which produced antidepressant-like effects in mice.

Is PE-22-28 legal?

It is not FDA-approved and is sold only as a research chemical.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy